We are live on
!
Find out more
LCOV
London Company of Virginia Portfolio holdings
AUM
$16.2B
1-Year Est. Return
17.5%
This Fund
S&P 500
This Quarter
Est. Return
+8.11%
1 Year Est. Return
+17.5%
3 Year Est. Return
+53.53%
5 Year Est. Return
+68.8%
10 Year Est. Return
+271.54%
AUM
$12.9B
AUM Growth
+$617M
(+5%)
Cap. Flow
-$259M
Cap. Flow
% of AUM
-2.01%
Top 10 Holdings %
Top 10 Hldgs %
32.24%
Holding
140
New
5
Increased
24
Reduced
87
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$232M |
| 2 |
Martin Marietta Materials
MLM
|
+$72.4M |
| 3 |
PACCAR
PCAR
|
+$65.5M |
| 4 |
Entegris
ENTG
|
+$62.6M |
| 5 |
Skyworks Solutions
SWKS
|
+$24.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Target
TGT
|
+$145M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$69.4M |
| 3 |
Deere & Co
DE
|
+$30.5M |
| 4 |
Cintas
CTAS
|
+$29.7M |
| 5 |
Progressive
PGR
|
+$26.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 19.21% |
| 2 | Technology | 17.49% |
| 3 | Financials | 16.24% |
| 4 | Consumer Discretionary | 12.24% |
| 5 | Consumer Staples | 10.43% |
Similar funds
UCFA
IG
EIP
CI
MG
CLGM
LCIP
London Company of Virginia's Q3 2018 Portfolio in Review
As of Q3 2018, London Company of Virginia held 140 positions worth $12.9B, up 5% from $12.2B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
London Company of Virginia's Q3 2018 filing shows 5 new, 24 increased, 87 reduced and 4 closed positions. Its largest new stake was Entegris: 1,860,389 shares worth $53.9M. The largest sale was Target, an estimated $145M.
By sector, the portfolio is most concentrated in Industrials at 19% of assets, up from 19% a quarter earlier, followed by Technology and Financials.
- London Company of Virginia's largest Q3 2018 buy was Entegris: 1,860,389 shares worth $53.9M.
- London Company of Virginia added most to Johnson & Johnson in Q3 2018, an estimated $232M increase.
- London Company of Virginia's biggest Q3 2018 reduction was Target, cutting an estimated $145M.
- London Company of Virginia fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $69.4M.
- London Company of Virginia's ten largest holdings make up 32% of its $12.9B portfolio in Q3 2018.
- London Company of Virginia opened 5 new positions and closed 4 in Q3 2018.
- London Company of Virginia's portfolio value rose 5% quarter-over-quarter to $12.9B.
Based on London Company of Virginia's 13F filing for Q3 2018, filed 14 Nov 2018.